Control BionicsASX:CBL -0.67% EPS without NRI is A$-0.02 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 665 Medical Devices & Instruments companies, Control Bionics ranks better than 75.34% on this metric.
Control Bionics's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was A$-0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 28.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Control Bionics's EPS without NRI or its related term are showing as below:
ASX:CBL'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 10.4 Med: 19.45 Max: 28.5
Current: 28.5
During the past 6 years, Control Bionics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 28.50% per year. The lowest was 10.40% per year. And the median was 19.45% per year.
ASX:CBL's 3-Year EPS without NRI Growth Rate is ranked better than 75.34% of 665
companies
in the Medical Devices & Instruments industry
Industry Median: 8.1
vs ASX:CBL: 28.50
Control Bionics's EPS (Diluted) for the
six
months ended in Dec. 2025 was A$-0.01.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.
Control Bionics's EPS (Basic) for the
six
months ended in Dec. 2025 was A$-0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.
Control Bionics (ASX:CBL) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Control Bionics EPS without NRI Related Terms
Control Bionics EPS without NRI Historical Data
* Premium members only.
The historical data trend for Control Bionics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CBL vs ABT, SYK, MDT: EPS without NRI Comparison
For the Medical Devices subindustry, Control Bionics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Control Bionics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a EPS without NRI of A$-0.02 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #164 out of 665 companies in the Medical Devices & Instruments industry, placing it in the top 24.7%.
Is Control Bionics' EPS without NRI too high?
Control Bionics' current EPS without NRI is A$-0.02. Based on the distribution chart, Control Bionics ranks #164 out of 665 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Control Bionics' EPS without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #164 out of 665 companies for EPS without NRI. This places Control Bionics in the top 25% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.10, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current EPS without NRI is A$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 146.7% above its estimated fair value. The current EPS without NRI is A$-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current EPS without NRI is A$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 